Dillan DiNardo is the CEO of Mindstate Design Labs - a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions.
Mindstate's mission is to map the biological basis of the varieties of psychedelic experience, and to use that map to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders.
Mindstate participated in Y Combinator in 2021.
Brom's Psychedelic VC fund, Empath Ventures is an investor in Mindstate.
Check out Mindstate @ https://www.mindstate.design/